Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NUVB vs TSHA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TSHA Captures Overall Composite Edge (49.8 HOLD vs 61.0 BUY), While NUVB Leads 4–1 on Growth & Valuation Pillars

TSHA Overall Winner 6-Pillar Tally: NUVB 4 – 1 TSHA (1 Tie) Matrix Metrics: NUVB 5 – 3 TSHA

As of Nov 20, 2026, Taysha Gene Therapies, Inc. (TSHA) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (49.8/100 HOLD vs. 61.0/100 BUY) after splitting the core matrix 3–5 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus TSHA at $3.72 (N/M Forward P/E, -2998.0% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. TSHA 49.8/100 HOLD), TSHA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-2998.0% vs. -61.2% operating margin) and revenue trajectory (+171.3% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile TSHA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NUVB vs TSHA
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87
TSHA NASDAQ Head-to-Head Winner
Taysha Gene Therapies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.72
-1.33% 1D
Market Cap $1.2B
TTM Revenue $5.5M
Forward P/E N/M
Beta / 30D Vol 1.81β · 52% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 35
RSI-14: 34.7 · SMA20: $4.12 · SMA50: $4.35

6-Pillar Scorecard Institutional Category Breakdown (NUVB 4 – 1 TSHA)

Columns: Metric · NUVB · TSHA
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x N/M
2. Growth & Scale NUVB
Revenue Growth (YoY) +242.6% +171.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $202M $5.5M
Market Cap $1.3B $1.2B
3. Profitability & Quality NUVB
Gross Margin 85.8% 100.0%
Operating Margin -61.2% -2998.0%
Net Profit Margin -67.4% 0.0%
Return on Equity (ROE) -49.1% -54.2%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$108M -$136M
Cash Flow Margin -53.6% N/A
Net Cash / Leverage $146M Net Debt (1.32x D/E) $399M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TSHA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 65.2% (26th %ile) 300.8% (34th %ile)
Put/Call OI Skew 0.24x (Call-Skewed) 0.46x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NUVB (5) vs TSHA (3)
Institutional Metric NUVB TSHA Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.2B Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+242.6% +171.3% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-61.2% -2998.0% Higher Margin NUVB
Net Profit Margin
Profitability
-67.4% 0.0% Higher Margin TSHA
Return on Equity (ROE)
Capital Efficiency
-49.1% -54.2% Higher ROE NUVB
52-Week Range Position
Momentum
2% ($4–$10) 7% ($3–$7) Stronger Trend TSHA
Beta / 30D Volatility
Risk Regime
1.52β · 55% Vol 1.81β · 52% Vol Lower Realized Risk TSHA
Unified Institutional Score
Composite Signal
61.0 / 100 (BUY) 49.8 / 100 (HOLD) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$202M $5.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.8% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($146M Net Debt (1.32x D/E)) -$136M ($399M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TSHA +12.03 pp
NUVB: -19.15% · TSHA: -7.12%
3M Horizon TSHA +6.1 pp
NUVB: -43.79% · TSHA: -37.69%
6M Horizon NUVB +12.75 pp
NUVB: -19.49% · TSHA: -32.24%
1Y Horizon TSHA +39.62 pp
NUVB: -46.85% · TSHA: -7.23%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NUVB Revenue TSHA Revenue NUVB Op. Margin TSHA Op. Margin Margin Leader
FY2022 N/A $0M N/A -6492.7% TSHA
FY2023 N/A $20M N/A -468.8% TSHA
FY2024 $10M $10M -7527.3% -1097.6% TSHA
FY2025 $60M $10M -338.7% -1130.6% NUVB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TSHA BREAKDOWN
138d in phase · OBV DISTRIBUTION
Current IV 300.8%
IV Percentile 34th %ile
Put/Call OI Skew 0.46x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TSHA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TSHA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -2998.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NUVB vs TSHA Key Questions & Quantitative Answers

As of Nov 20, 2026, Taysha Gene Therapies, Inc. (TSHA) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (49.8/100 HOLD vs. 61.0/100 BUY) after splitting the core matrix 3–5 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus TSHA at $3.72 (N/M Forward P/E, -2998.0% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. TSHA 49.8/100 HOLD), TSHA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-2998.0% vs. -61.2% operating margin) and revenue trajectory (+171.3% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile TSHA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with TSHA at +171.3% YoY revenue growth and +0.0% YoY earnings growth on $5.5M TTM revenue (100.0% gross margin, -2998.0% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), NUVB cumulative revenue shifted +500.0% while TSHA shifted -50.0%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TSHA.

NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas TSHA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus TSHA (-54.2% ROE) capital efficiency.

In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, TSHA carries 300.8% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.46x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.